• 1
    Hogg G, Lima V, Sterne JA et al. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372: 293299.
  • 2
    Braithwaite RS, Justice AC, Chang CC et al. Estimating the proportion of patients infected with HIV who will die of comorbid diseases. Am J Med 2005; 118: 890898.
  • 3
    May MT, Sterne JA, Costagliola D et al. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet 2006; 368: 451458.
  • 4
    D'Arminio Monforte A, Sabin CA, Phillips A et al. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med 2005; 165: 416423.
  • 5
    Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Morbid Mortal Wkly Rep 1987; 36: 8294.
  • 6
    Lohse N, Hansen AB, Pedersen G et al. Survival of persons with and without HIV infection in Denmark, 1995–2005. Ann Intern Med 2007; 146: 8795.
  • 7
    Krentz HB, Kliewer G, Gill MJ. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. HIV Med 2005; 6: 99106.
  • 8
    Palella FJ Jr, Baker RK, Moorman AC et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV Outpatient Study. J Acquir Immune Defic Syndr 2006; 43: 2734.
  • 9
    El-Sadr WM, Lundgren JD, Neaton JD et al. CD4 count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 22832296.
  • 10
    Phillips AN, Neaton J, Lundgren JD. The role of HIV in serious diseases other than AIDS. AIDS 2008; 22: 24092418.
  • 11
    May M, Sterne JA, Sabin C et al. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007; 21: 11851197.
  • 12
    Chene G, Sterne JA, May M et al. Prognostic importance of initial response in HIV-1-infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 2003; 362: 679686.
  • 13
    Egger M, May M, Chene G et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360: 119129.
  • 14
    Mocroft AJ, Johnson MA, Sabin CA et al. Staging system for clinical AIDS patients. Lancet 1995; 346: 1217.
  • 15
    Moore RD, Forney D. Anemia in HIV-infected patients receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 29: 5457.
  • 16
    Mocroft A, Kirk O, Barton SE et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA Study Group. AIDS 1999; 13: 943950.
  • 17
    Sullivan PS, Hanson DL, Chu SY, Jones JL, Ward JW. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV Disease Surveillance Project. Blood 1998; 91: 301308.
  • 18
    The Antiretroviral Therapy Cohort Collaboration. Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir Ther 2008; 13: 959967.
  • 19
    Justice AC, Wagner JH, Fusco GP et al. HIV survival: liver function tests independently predict survival. 14th International AIDS Conference, Barcelona, Spain, July 2002.
  • 20
    Bica I, McGovern B, Dhar R et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 492497.
  • 21
    Puoti M, Spinetti A, Ghezzi A et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr 2000; 24: 211217.
  • 22
    Fine DM, Atta MG. Kidney disease in the HIV-infected patient. AIDS Patient Care STDS 2007; 21: 813824.
  • 23
    Wyatt CM, Klotman PE. HIV-associated nephropathy in the era of antiretroviral therapy. Am J Med 2007; 120: 488492.
  • 24
    Fultz SL, Skanderson M, Mole LA et al. Development and verification of a ‘virtual’ cohort using the National VA Health Information System. Med Care 2006; 44: S25S30.
  • 25
    Justice AC, Dombrowski E, Conigliaro J et al. Veterans Aging Cohort Study (VACS): overview and description. Med Care 2006; 44: S13S24.
  • 26
    Backus L, Mole L, Chang S, Deyton L. The immunology case registry. J Clin Epidemiol 2001; 54: S12S15.
  • 27
    Sales MM, Cunningham FE, Glassman PA, Valentino MA, Good CB. Pharmacy benefits management in the Veterans Health Administration: 1995 to 2003. Am J Manage Care 2005; 11: 104112.
  • 28
    Justice AC, Lasky E, McGinnis KA et al. Medical disease and alcohol use among veterans with human immunodeficiency infection: a comparison of disease measurement strategies. Med Care 2006; 44: S52S60.
  • 29
    Cowper DC, Kubal JD, Maynard C, Hynes DM. A primer and comparative review of major US mortality databases. Ann Epidemiol 2002; 12: 462468.
  • 30
    Fisher SG, Weber L, Goldberg J, Davis F. Mortality ascertainment in the veteran population: alternatives to the National Death Index. Am J Epidemiol 1995; 141: 242250.
  • 31
    Justice AC, Covinsky KE, Berlin JA. Assessing the generalizability of prognostic information. Ann Intern Med 1999; 130: 515524.
  • 32
    May M, Royston P, Egger M, Justice AC, Sterne JA. Development and validation of a prognostic model for survival time data: application to prognosis of HIV-positive patients treated with antiretroviral therapy. Stat Med 2004; 23: 23752398.
  • 33
    Sterling RK, Lissen E, Clumeck N et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 13171325.
  • 34
    Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 2006; 354: 24732483.
  • 35
    Goulet JL, Fultz SL, Rimland D et al. Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity? Clin Infect Dis 2007; 45: 15931601.
  • 36
    Knaus WA, Zimmerman JE, Wagner DP, Draper EA, Lawrence DE. APACHE-acute physiology and chronic health evaluation: a physiologically based classification system. Crit Care Med 1981; 9: 591597.
  • 37
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40: 373383.
  • 38
    Effros RB, Fletcher CV, Gebo K et al. Aging and infectious diseases: what is known and future research directions. Clin Infect Dis 2008; 47: 542553.
  • 39
    Justice AC. The Development, Validation, and Evaluation of Prognostic Systems: An Application to the Acquired Immunodeficiency Syndrome (AIDS). Ann Arbor, MI: UMI Number 9627942, PhD Dissertation, 1996.
  • 40
    Den Boer S, De Keizer NF, De Jonge E. Performance of prognostic models in critically ill cancer patients – a review. Crit Care 2005; 9: R458R463.
  • 41
    Arabi Y, Al Shirawi N, Memish Z, Venkatesh S, Al-Shimemeri A. Assessment of six mortality prediction models in patients admitted with severe sepsis and septic shock to the intensive care unit: a prospective cohort study. Crit Care 2003; 7: R116R122.
  • 42
    Render ML, Welsh DE, Kollef M et al. Automated computerized intensive care unit severity of illness measure in the Department of Veterans Affairs: preliminary results. SISVistA Investigators. Scrutiny of ICU severity Veterans Health Systems technology architecture. Crit Care Med 2000; 28: 35403546.
  • 43
    Chaudhry S, Jin L, Meltzer D. Use of a self-report-generated Charlson Comorbidity Index for predicting mortality. Med Care 2005; 43: 607615.
  • 44
    Kohli R, Lo Y, Howard AA et al. Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 41: 864872.
  • 45
    Conigliaro J, Justice AC, Gordon AJ, Bryant K. Role of alcohol in determining human immunodeficiency virus (HIV)-relevant outcomes: a conceptual model to guide the implementation of evidence-based interventions into practice. Med Care 2006; 44: S1S6.
  • 46
    Effros RB, Allsopp R, Chiu C-P et al. Shortened telomeres in the expanded CD28− CD8+cell subset in HIV disease implicate replicative senescence in HIV pathogenesis. AIDS 1996; 10: F17F22.
  • 47
    De Gruttola VG, Clax P, DeMets DL et al. Considerations in the evaluation of surrogate endpoints in clinical trials. Summary of a National Institutes of Health workshop. Control Clin Trials 2001; 22: 485502.
  • 48
    Harrell FE, Lee KL, Mark DB. Tutorial in biostatistics. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361387.
  • 49
    Lynn J, Teno JM, Harrell FE, Jr. Accurate prognostications of death. Opportunities and challenges for clinicians. West J Med 1995; 163: 250257.
  • 50
    Harrell FE, Lee KL, Matchar DB, Reichert TA. Regression models for prognostic prediction: advantages, problems and suggested solutions. Cancer Treatment Rep 1985; 69: 10711077.
  • 51
    Fleming TR, Prentice RL, Pepe MS, Glidden D. Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research. Stat Med 1994; 13: 955968.
  • 52
    HIV Surrogate Marker Collaborative Group. Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: a meta-analysis. AIDS Res Hum Retroviruses 2000; 16: 11231133.